


PRODUCT INFORMATION



BW 755C

Item No. 15490

CAS Registry No.: 66000-40-6
Formal Name: 4,5-dihydro-1-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-amine
MF: C₁₀H₁₀F₃N₃
FW: 229.2
Purity: ≥95%
UV/Vis.: λ_{max}: 286 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BW 755C is supplied as a crystalline solid. A stock solution may be made by dissolving the BW 755C in the solvent of choice, which should be purged with an inert gas. BW 755C is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of BW 755C in ethanol and DMSO is approximately 30 mg/ml and approximately 25 mg/ml in DMF.

BW 755C is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BW 755C should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. BW 755C has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

BW 755C is a dual inhibitor of 5-lipoxygenase (5-LO) and cyclooxygenase (COX) pathways, inhibiting 5-LO, COX-1, and COX-2 (IC₅₀s = 0.75 μM, 0.65 μg/ml, and 1.2 μg/ml, respectively).{25336,25335,1287} It may also inhibit other LO pathways *in vivo*.{67} Through these actions, BW 755C diminishes inflammation. {744,23775}

References

1. Aizawa, Y., Kanai, T., Hasegawa, K., *et al.* Studies on hindered phenols and analogues. 2. 1,3-Benzoxathioles having SRS-A inhibiting activity. *J. Med. Chem.* **33**(5), 1491-1496 (1990).
2. Hlasta, D.J., Casey, F.B., Ferguson, E.W., *et al.* 5-Lipoxygenase inhibitors: The synthesis and structure-activity relationships of a series of 1-phenyl-3-pyrazolidinones. *J. Med. Chem.* **34**(5), 1560-1570 (1991).
3. Mitchell, J.A., Akarasereenont, P., Thiemermann, C., *et al.* Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. *Proc. Natl. Acad. Sci. USA* **90**, 11693-11697 (1993).
4. Tanaka, N., Espey, L.L., Kawano, T., *et al.* Comparison of inhibitory actions of indomethacin and epostane on ovulation in rats. *Am. J. Physiol.* **260**, E170-E174 (1991).
5. Higgs, G.A., Flower, R.J., and Vane, J.R. A new approach to anti-inflammatory drugs. *Biochem. Pharmacol.* **28**, 1959-1961 (1979).
6. Calhoun, W., Yu, J., Sung, A., *et al.* Pharmacologic modulation of D-49 phospholipase A₂-induced paw edema in the mouse. *Agents Actions* **27**, 418-421 (1989).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/09/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM